Industry News
-
AAV-Mediated Parkin Gene Therapy Shows Promising Rescue of Dopaminergic Neurons in Parkinson’s Disease Models
Mar 05 2026 -
Passage Bio Advances AAV Gene Therapy Program for Frontotemporal Dementia and Expands Neurodegenerative Pipeline
Mar 04 2026 -
FDA Details Reasons for Rejecting Regenxbio’s AAV Gene Therapy RGX-121 for Hunter Syndrome
Mar 04 2026 -
Bayer Prioritizes AAV Gene Therapy AB-1009 for Pompe Disease
Mar 04 2026 -
Cure Rare Disease and LGMD2L Foundation Announce Gene Therapy Partnership for ANO5-Related Disease
Mar 03 2026 -
New HIT Receptor Technology Enables CAR-T Cells to Detect Low-Antigen Tumor Cells in Solid Cancers
Mar 03 2026 -
FDA Lifts Clinical Hold on Intellia’s Phase 3 CRISPR Therapy Trial
Mar 02 2026 -
Ocugen Completes Phase 3 Enrollment for OCU400 Gene-Agnostic AAV Therapy in Retinitis Pigmentosa
Mar 02 2026 -
Opus Genetics Reports Early Phase I/II Data for OPGx-BEST1 AAV Gene Therapy in BEST1 Retinal Diseases
Mar 02 2026